Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / CDH1



This biomarker is also known as:
  • CD324,
  • CAM 120/80,
  • E-Cadherin,
  • Cadherin-1,
  • cadherin 1, type 1, E-cadherin (epithelial),
  • CDHE,
  • uvomorulin,
  • UVO,

View in BioMuta


The CDH1 gene is a classical cadherin from the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization. CDH1 has a potent invasive suppressor role.


QA State: Curated
Type: Genomic
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



QA State:


Performance Comment



Phase: One
QA State: Curated


Cadherins are cell-cell adhesion molecules. Lower levels of cadherins, particulary CDH1 (E-cadherin), can cause the cell to be unable to adhere, resulting in a loss of the normal architecture of tissues. This effect has been seen with CDH1 and lung cancer.

Performance Comment

CDH1 has been identified in serum and lung cancer tissue or cell culture as a candidate lung cancer biomarker. It has also been suggested as a biomarker to differentiate between bronchioloalveolar carcinoma and conventional pulmonary carcinoma, and between mesothelioma and metastatic pulmonary adenocarcinoma. CDH1 is also a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.



Phase: One
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.